“gold standard”, were set at 100%, while ranges for sensitivity and specificity for MRA were drawn from literature and used for sensitivity analysis. Analyses performed for a hypothetical population of 91,665 (US diabetics with PAD who are eligible for treatment in 2000) included: one-year total health care costs, total Quality Adjusted Life Year Gained (QALYG; the increase in quality of life after treatment), cost per QALYG, incremental cost per QALY, and cost of accurate and inaccurate planning with medical management, PTA, bypass, and amputation.

RESULTS: In the base-case scenario, with MRA sensitivity and specificity at 98% and 83% respectively, the one-year per patient total health care costs in the diabetic PAD population was $20,176 for patients receiving an MRA versus $21,996 for those receiving a DSA for treatment planning. The total QALYG were higher in the MRA cohort than in the DSA cohort, 0.11 versus 0.07 respectively. Therefore, the total cost per QALYG was $106,948 higher for patients who received a DSA ($190,697 vs. $297,645). MRA dominates the DSA in incremental cost/QALY with savings of $37,060, due to a lower risk of complication and the resultant greater increase in QALYG and lower cost of treatment. CONCLUSION: This model demonstrates that MRA as a treatment-planning tool, with lower risk of complication, could substantially reduce the cost and cost per quality-adjusted life years for peripheral arterial disease in diabetic patients.

PCV19

COST COMPARISON OF DIFFERENT TREATMENTS FOR DEEP VEIN THROMBOSIS PROPHYLAXIS DURING ABDOMINAL SURGERY

Patel VA, McGhan WF

University of the Sciences in Philadelphia, Philadelphia, PA, USA

OBJECTIVES: Nearly 600,000 patients are diagnosed with Deep Vein Thrombosis (DVT) in US every year. One in every 100 patient dies due to pulmonary embolism developed as a later complication. DVT during abdominal surgery is a frequent problem & therefore prophylaxis is a compulsion. The objective of this study was to identify the least costly prophylactic treatment taking into account DVT complications from the health care payer perspective. METHODS: Cost comparison was done using a decision tree. The probabilities and costs for postoperative DVT was obtained from clinical trial studies and other published sources. Prophylaxis during surgery was considered to be for 9 days whereas treatment for postoperative DVT was assumed to be for 5 days. Total cost included drug acquisition cost, hospitalization costs for DVT. Expected value was computed at each chance node. RESULTS: Fondaparinux sodium has the least probability (0.042) for postoperative DVT complications whereas Enoxaparin sodium & unfractionated heparin (UFH) have higher probabilities of 0.048 & 0.11 respectively. The drug acquisition cost for prophylaxis was highest with fondaparinux sodium (2.5 mg) at $36.69, enoxaparin sodium (40 mg) at $24.74 & UFH (5000 IU) at $3.06 per single dose. Low molecular weight heparins were given once daily while UFH was given twice daily. Expected value was found to be $1129.720, $1133.590 & $2256.730 for fondaparinux sodium, enoxaparin sodium & UFH respectively. Sensitivity Analysis showed that the model is somewhat influenced by adverse events & costs. CONCLUSION: Fondaparinux sodium has been found to have the least costly prophylactic treatment. Although the acquisition cost is the highest, it is offset by the low probability of developing DVT complications and later hospitalization costs. UFH even though having the lowest acquisition cost, has high rate of DVT complications & higher hospitalization cost due to frequent administration procedures & continuous monitoring requirement.

PCV20

A COST-EFFECTIVENESS STUDY COMPARING IVABRADINE WITH STANDARD CARE IN STABLE ANGINA PECTORIS IN THE NETHERLANDS

Redekop WK1, Nuijten MJ2

1Erasmus Medical Center, Rotterdam, The Netherlands, 2Erasmus University, Rotterdam, The Netherlands

OBJECTIVES: To compare the costs resulting from a treatment with ivabradine, a new medication for stable angina pectoris patients, with standard care for those patients who cannot be appropriately treated with standard medication in The Netherlands in 2006. METHODS: A decision analytic model was used to estimate the cost-effectiveness of ivabradine in patients with stable angina pectoris, who cannot be appropriately treated with standard medication and are therefore currently candidates for revascularisation (ESC guidelines 2006 on the management of stable angina pectoris). Therefore ivabradine is compared with standard care consisting of revascularization (CABG or PTCA). The study was performed within the society perspective, which included costs of medication and revascularisation procedures. The data sources included published literature, the ivabradine clinical trials, the Euro Heart Survey for stable angina, which provided data from daily practice, and official price/tariff lists and national population statistics. RESULTS: Treatment with ivabradine results in 77% reduction in revascularisation and leads to a cost saving of €7028 per patient compared with revascularisation during the first year of treatment. Sensitivity analyses showed that extrapolation beyond one year leads to further cost savings. Another sensitivity analysis on the probability of revascularisation showed that cost savings vary from €2882 to €9102. CONCLUSION: This model showed that the use of ivabradine compares favourably with revascularisation in treatment of stable angina pectoris in The Netherlands from a budgetary and health economic perspective: the total costs are substantially lower, whereas the effectiveness is at least similar. Consequently ivabradine can be considered a cost-effective treatment being dominant over standard care.

PCV21

ECONOMIC EVALUATION OF EPLERENONE COMPARED WITH PLACEBO IN PATIENTS WITH MYOCARDIAL INFARCTION COMPLICATED BY LEFT VENTRICULAR SYSTOLIC DYSFUNCTION AND HEART FAILURE IN MEXICO

Mould-Quevedo J, Salomon-Molina A, Davila-Loaiza G

Pfizer Mexico, Mexico City, Mexico

OBJECTIVES: In Mexico in 2005, there are more than 250,000 patients in secondary prevention. One of the most serious and frequent consequences of survivors of acute myocardial infarction (AMI) is heart failure, which is associated with a 55% greater risk of dying and 2.15-times greater risk of death or recurrent AMI at 30 days. The purpose of this study was to evaluate the cost—effectiveness of eplerenone compared with placebo from the Mexican health care payer’s perspective. METHODS: We used a three-year analysis model to estimate costs and effectiveness. Effectiveness measures were the number of life-year gained (LYG) and quality-adjusted life-years (QALYs). Effectiveness data was obtained from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Survival beyond the trial period (16 months) was estimated from data from the Framingham Heart Study. The estimation of resource use was performed employing local expert opinion surveys and they included hospitalization, emergency room visits, outpatient services and medication. Costs and life expectancy differences were discounted 5% annually. Threshold sensitivity analysis was performed and acceptability